Page 1 of

Post-Autologous BMT infectious Disease Prophylaxis Survey

GOAL: Survey to access multiple Pediatric BMT Units/Clinicians clinical practice regarding HSV, fungal, and bacterial prophylaxis post autologous BMT (auto). My ultimate goal is to establish an evidence based guideline regarding duration of post autologous BMT prophylaxis. Your completion of this survey will help me determine current practices in the field.

	Several questions will allow multiple answers.	
	We welcome any comments/suggestions at the end of survey.	
l	Does the transplant team remain the primary service for pediatric autologous HSCT patients following transplant at discharge?	YesNo
	for how long on average?	<pre>< 3 months 3-6 months 6-12 months >12 months other</pre>
	other, please explain:	
	Managed by oncology service?	
2	Do you have a standard practice for Herpes Simplex Virus-1 prophylaxis during autologous HSCT?	○ Yes ○ No
	What medication is used for prophylaxis?	☐ Acyclovir ☐ Valacyclovir ☐ Ganciclovir ☐ other
	other, please explain:	
	What is the duration for prophylaxis?	<pre></pre>
	Other, please explain:	
3	Do you have a standard practice for fungal prophylaxis during autologous HSCT?	



	What antifungal medication is used for prophylaxis?	☐ Fluconazole ☐ Micafungin ☐ Voriconazole ☐ Posaconazole ☐ Ambisome ☐ Other:
	Other, please explain:	
	What is the duration of prophylaxis	<pre></pre>
	other, please explain:	
4	Do you have a standard practice for bacterial prophylaxis during autologous HSCT?	Yes No
	What do you use for bacterial prophylaxis?	☐ Cefepime ☐ Ceftazidime ☐ Zosyn ☐ Other:
	Other, please explain:	
	What is the duration ?	 Until ANC >500 < 3 months 3-6 months 6-12 months > 12 months Other:
	other, please explain:	
5	Does your institution routinely screen for viral infections after autologous HSCT?	
	which viruses are screened?	☐ CMV ☐ EBV ☐ Adenovirus ☐ HHV6 ☐ other
	other, please explain	
	At what frequency is screening performed?	 Once per week Twice per week Once per month Never screened, only if symptoms require testing
6	For questions #3-5, is this practice based on published literature or local data?	○ Yes ○ No

REDCap €

Page 3 of 3

	Please explain:	
7	Do you routinely monitor immune reconstitution following autologous HSCT?	○ Yes ○ No
	What aspects of the immune system do you follow?	☐ antibody levels ☐ CD3 ☐ CD4 ☐ CD8 ☐ CD19 ☐ Mitogen stimulation testing ☐ Other
	other, please explain:	
8	Do you rely on immune reconstitution to determine length of prophylaxis following autologous HSCT? What are your target cell numbers and/or function?	○ Yes ○ No
	what are your target cen numbers and/or function:	
9	Comments:	

